As their intro paragraph notes below....we know that anti-PD1 alone or combined with ipi does better than ipi alone. We know the response rate to ipi is about 15-20%. We know that response rates to either anti-PD1 product (Nivo/Opdivo or Pembro/Keytruda) are about 40%. We know that the ipi/nivo combo response rate is about 50% or a little better. Here...though...they looked at folks who had failed anti-PD1 as a single agent and tried treating them with either ipi alone or the ipi/nivo combo....
A multicenter retrospective study in advanced melanoma patients who were treated with nivolumab (1 or 3 mg/kg) and ipilimumab (1 mg or 3 mg/kg) or ipilimumab (3 mg/kg) alone after treatment failure to anti-PD-1 therapy was performed. Patient, tumour, pre- and post-treatment characteristics were analysed.
In total, 47 patients were treated with ipilimumab (ipi-group) and 37 patients with ipilimumab and nivolumab (combination-group) after treatment failure to anti-PD-1 therapy. Overall response rates for the ipi- and the combination-group were 16% and 21%, respectively. Disease control rate was 42% for the ipi-group and 33% for the combination-group. One-year overall survival rates for the ipi- and the combination-group were 54% and 55%, respectively.
Ipilimumab should be considered as a viable treatment option for patients with failure to prior anti-PD-1 therapy, including those with progressive disease as best response to prior anti-PD-1. In contrast, the combination of ipilimumab and nivolumab appears significantly less effective in this setting compared to treatment-naïve patients.
Sooo....while response rates were not as great as they are for the treatment naive patients.... a 21% response rate to the ipi/nivo combo can still be attained for those who have failed anti-PD1 as a single agent.
I wish you well. - c